Cannabis-based medicine for neuropathic pain
Pro Research Analysisby 
Searched over 200M research papers
Cannabis-Based Medicine for Neuropathic Pain: Efficacy and Safety
Effectiveness of Cannabis-Based Medicines for Neuropathic Pain
Research shows that cannabis-based medicines (CBMs), including herbal cannabis, plant-derived, and synthetic cannabinoids, may provide some pain relief for adults with chronic neuropathic pain, but the benefits are generally modest. Several systematic reviews and meta-analyses found that CBMs can increase the number of people achieving at least 30% pain relief compared to placebo, but the improvement is small and the quality of evidence is low to moderate Mücke2018Petzke2021Sainsbury2021+1 MORE. Some studies found that THC and THC/CBD combinations are more likely to reduce pain intensity than placebo, but the overall effect size is limited and not all cannabinoids (such as CBD alone) show significant benefit .
Comparison with Other Treatments and Clinical Recommendations
When compared to other commonly used medications for neuropathic pain, such as gabapentinoids, duloxetine, and tricyclic antidepressants, CBMs may have a similar or slightly better benefit–safety profile, especially in terms of quality of life and side effect burden . However, most medical guidelines recommend CBMs only as a third-line or alternative therapy, to be considered when standard treatments have failed or are not tolerated Petzke2021Häuser2018. The European Pain Federation suggests that CBMs should be prescribed by experienced clinicians as part of a multidisciplinary approach and only after first- and second-line therapies have proven insufficient .
Safety, Tolerability, and Side Effects
CBMs are associated with a higher risk of adverse events compared to placebo. Common side effects include nervous system disorders (such as dizziness and somnolence) and psychiatric symptoms (such as anxiety and mood changes) Mücke2018Petzke2021Sainsbury2021. Withdrawal due to adverse events is more frequent with CBMs than with placebo . Serious adverse events are rare, but the long-term safety of CBMs remains unclear due to a lack of long-term studies Mücke2018Petzke2021Häuser2018. Some reviews highlight that the side effect profile of CBMs may be more favorable than opioids and some other pain medications, but careful monitoring is still required Nutt2021Häuser2018.
Evidence from Recent Clinical Trials
Recent randomized controlled trials, including those involving patients with multiple sclerosis or spinal cord injury, have not found significant differences between CBMs (THC, CBD, or their combination) and placebo in reducing neuropathic pain or spasticity . These findings suggest that while some patients may benefit, the overall effect in larger, more diverse populations is limited .
Clinical Practice and Future Research
There is ongoing debate and variation in recommendations for the use of CBMs in neuropathic pain. Some case reports and clinical experiences suggest that CBMs can be a useful adjunct for difficult-to-treat cases, but more high-quality, long-term studies are needed to confirm their role and to optimize dosing, cannabinoid ratios, and administration routes Lee2018Jacob2024. Realistic treatment goals and close clinical monitoring are essential when using CBMs for neuropathic pain .
Conclusion
Cannabis-based medicines may offer modest pain relief for some adults with chronic neuropathic pain, but the benefits are often small and must be weighed against the risk of side effects. Current evidence supports their use mainly as an adjunct or third-line therapy when standard treatments are ineffective or not tolerated. More research is needed to clarify their long-term safety, optimal use, and effectiveness in broader patient populations.
Sources and full results
Most relevant research papers on this topic